PRESS RELEASE
MITHRA PHARMACEUTICALS TO HOST INVESTOR DAY EVENT ON JUNE 29TH, 2016 IN BRUSSELSLiège, Belgium 25 May 2016 - Mithra announces that it will host its Investor Day event on June 29th 2016 in Brussels from 8:30 AM to 5:30 PM in the attendance of the CEO François Fornieri, Jean- Michel Foidart as a member of the Scientific Committee and other Mithra executives.
Mithra will provide an update on its strategic plan and present an overview of its operations, R&D developments and outlooks for the upcoming years. The event will include presentations and Q&A with the Executive Team, led by the CEO, François Fornieri.
Program:8:30 - 9:00 | Registration |
9:00 - 9:05 | Welcome (Jean-Manuel Fontaine) |
9:05 - 10:05 | The unique potential of Estetrol (Jean-Michel Foidart) |
10:05 - 11:05 | Company and Financial Update with CEO and CFO |
11:05 - 11:45 | Q&A panel |
11:45 - 13:30 | Drink and lunch with management |
13:30 - 14:30 | Focus on Estetrol based projects (Estetrol-Estelle-Donesta) |
14:30 - 14:45 | Coffee Break |
14:45 - 15:45 | Focus on controlled release products and CDMO |
15:45 - 16:15 | Q&A panel and Wrap up |
16:15 - 17:30 | Drink |
All investors, analysts and members of the financial community interested in attending have to register in advance. For those who are unable to attend in person, Mithra will webcast a live video of the meeting via its website investors.mithra.com.
Event registration and further information by e-mail to investorrelations@mithra.com
PicturesFor pictures of François Fornieri, please click here on the following link: http://www.mithra.com/en/logo/
For more information, please contact:Press
Julie DessartChief Communication Officer
+32 4 349 28 22
+32 475 86 41 75
press@mithra.com
Investor Relations
François Fornieri, CEO+32 4 349 28 22
investorrelations@mithra.com
About MithraMithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.
Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com
Important informationThe contents of this announcement include statements that are, or may be deemed to be, "forward- looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
To subscribe to Mithra's newsletter, visit investors.mithra.com
Mithra Pharmaceuticals SA published this content on 25 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 May 2016 07:10:02 UTC.
Original documenthttp://investors.mithra.com/wp-content/uploads/2016/05/2016-05-25-Investor-Day-EN-FINAL.pdf
Public permalinkhttp://www.publicnow.com/view/A65685324D7F5846404A032AD2392F5F2D193320